Portal de Periódicos da CAPES

The Impact of Drug Resistance on the Effectiveness of Chemotherapy for Chronic Hepatitis B

2000; Lippincott Williams & Wilkins; Volume: 32; Issue: 4 Linguagem: Inglês

10.1053/jhep.2000.18194

1527-3350

Douglas D. Richman,

HIV/AIDS drug development and treatment

HepatologyVolume 32, Issue 4 p. 866-867 EditorialFree Access The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B Douglas D. Richman M.D., Corresponding Author Douglas D. Richman M.D. [email protected] San Diego Veterans Affairs Healthcare System, University of California San Diego, Departments of Pathology and Medicine, La Jolla, CASan Diego Veterans Affairs Healthcare System and University of California San Diego, Departments of Pathology and Medicine, 0679, 9500 Gilman Drive, La Jolla, CA 92093-0679. fax: 858-552-7445===Search for more papers by this author Douglas D. Richman M.D., Corresponding Author Douglas D. Richman M.D. [email protected] San Diego Veterans Affairs Healthcare System, University of California San Diego, Departments of Pathology and Medicine, La Jolla, CASan Diego Veterans Affairs Healthcare System and University of California San Diego, Departments of Pathology and Medicine, 0679, 9500 Gilman Drive, La Jolla, CA 92093-0679. fax: 858-552-7445===Search for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2000.18194Citations: 68AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1 Richman DD. Antiviral drug resistance: issues and challenges. In: DD Richman eds. Antiviral Drug Resistance. Chichester: John Wiley and Sons. 1996; 1– 9. 2 Drake JW, Holland JJ. Mutation rates among RNA viruses. Proc Natl Acad Sci U S A 1999; 96: 13910– 13913.MEDLINE 3 Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifetime, and viral generation time. Science 1996; 271: 1582– 1586.MEDLINE 4 Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93: 4398– 4402.MEDLINE 5 Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29: 1863– 1869.MEDLINE 6 Lau DT-Y, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828– 834.MEDLINE 7 McCoughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, Verran D, et al. Lamivudine therapy in patient undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 512– 519.MEDLINE 8 Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302– 1306.MEDLINE 9 Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711– 1716.MEDLINE 10 Cane PA, Mutimer D, Ratcliffe D, Cook P, Beards G, Elias E, Pillay D. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antiviral Therapy 1999; 4: 5– 12.MEDLINE 11 Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13: F123– F127.MEDLINE 12 DD Richman, ed. Antiviral Drug Resistance. Chichester: John Wiley & Sons. 1996; 1– 303. 13 Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH. Herpes simplex virus resistant to acyclovir. Ann Intern Med 1990; 112: 416– 422.MEDLINE 14 Safrin S, Crumpacker C, Chatis P, Davis R, Hafner R, Rush J, Kessler HA, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991; 325: 551– 555.MEDLINE 15 Lai C-J, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61– 68.MEDLINE 16 Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743– 758.MEDLINE 17 Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581– 1586.MEDLINE 18 Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13: 2349– 2359.MEDLINE 19 Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968– 975.MEDLINE 20 Tillmann HL, Trautwein C, Bock T, Boker KHW, Jackel E, Glowienka M, Oldhafer K, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999; 30: 244– 256.MEDLINE 21 Wong JK, Hezareh M, Günthard H, Havlir DV, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291– 1294.MEDLINE 22 Finzi D, Hermankova M, Pierson T, Carruth LM, Chaisson RE, Quinn TC, Brookmeyer R, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295– 1300.MEDLINE Citing Literature Volume32, Issue4October 2000Pages 866-867 ReferencesRelatedInformation